Condition: Homozygous Familial Hypercholesterolemia · Sponsor: First Affiliated Hospital Xi'an Jiaotong University
This is an early phase 1, open-label, single-center, dose-escalation, pilot trial to evaluate the safety and efficacy of an intravenous infusion of NGGT006 in homozygous familial hypercholesterolemia (HoFH) patients with LDLR mutations. NGGT006 is an adeno-associated viral (AAV) vector carrying codon-optimized human LDLR gene, driving the expression of LDLR protein with normal function and promoting the clearance of low-density lipoprotein cholesterol (LDL-C).
This description comes directly from the study's public registry record.
Tao Zheng, M.D. · 086-15229218127 · zhengtao900305@163.com
Ge Gao, M.M. · 086-18229068097 · gaoge1030@163.com
Always discuss trial participation with your own doctor first.
| First Affiliated Hospital of Xian Jiaotong University | Xi'an, Shaanxi, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06125847